T-Cell Therapy (ECT204) in Adults With Advanced HCC
Phase 1/2
20
about 5.8 years
18+
6 sites in CA, KS, NY +3
What this study is about
Researchers are testing a new treatment called ECT204 T cells for adults with advanced liver cancer. The trial will evaluate the safety of this treatment and see if it works to some degree.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive ECT204 T cells
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Assess the safety and tolerability of ECT204 in adult subjects with advanced HCC
Secondary: Assess the efficacy of ECT204 | Disease Control Rate, Assess the efficacy of ECT204 | Duration of Response, Assess the efficacy of ECT204 | Overall Survival, Assess the efficacy of ECT204 | Progression-Free Survival, Assess the efficacy of ECT204 | Time to Progression (TTP), Characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204, in our study subject population | Other relevant PK parameters in peripheral blood (PB), Characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204, in our study subject population | Partial area under the curve (pAUC), Characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204, in our study subject population | Peak Exposure (Cmax)